
Please try another search
Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes brain health medicines. The company offers ZURZUVAE, a neuroactive steroid positive allosteric modulator of GABA receptors targeting synaptic and extrasynaptic GABA receptors for the treatment of postpartum depression in adults. Its product pipeline also includes SAGE-324, a novel GABA receptor positive allosteric modulator for chronic oral dosing, including seizures in developmental and epileptic encephalopathies; and SAGE-319, an extrasynaptic-preferring GABA receptor positive allosteric modulator PAM for treating behavioral symptoms associated with neurodevelopmental disorders. In addition, the company is developing various product candidates, including SAGE-817 and SAGE-039 for the treatment of acute and chronic brain health disorders, including work on allosteric modulation of the GABA and NMDA receptor systems in the brain, as well as NMDA receptor negative allosteric modulator focusing on the treatments for neurodevelopmental disorders. The company was formerly known as Sterogen Biopharma, Inc. and changed its name to Sage Therapeutics, Inc. in September 2011. Sage Therapeutics, Inc. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts.
Name | Age | Since | Title |
---|---|---|---|
Scott Runyon | - | - | Member of Scientific Advisory Board |
A. Leslie Morrow | - | - | Member of Scientific Advisory Board |
Stephen Moss | - | - | Member of Scientific Advisory Board |
Stephen F. Traynelis | - | - | Member of Scientific Advisory Board |
James E. Audia | 69 | - | Member of Scientific Advisory Board |
David H. Farb | - | - | Member of Scientific Advisory Board |
Christine Marx | - | - | Member of Scientific Advisory Board |
Donald Stein | - | - | Member of Scientific Advisory Board |
Charles Zorumski | - | - | Member of Scientific Advisory Board |
Barry E. Greene | 62 | 2020 | President, CEO & Director |
James M. Frates | 58 | 2014 | Independent Director |
Geno J. Germano | 64 | 2016 | Independent Chair of the Board |
Elizabeth A. Barrett | 63 | 2019 | Independent Director |
George S. Golumbeski | 68 | 2019 | Independent Director |
Michael F. Cola | 65 | 2014 | Independent Director |
Jessica J. Federer | 43 | 2023 | Independent Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review